Damora Therapeutics (DMRA) Change in Accured Expenses (2019 - 2026)

Damora Therapeutics has reported Change in Accured Expenses for 8 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 854.11% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 428.94% YoY), and the FY2025 full-year result was $1.1 million, up 135.01% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $3.6 million, up from -$182000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.6 million in Q1 2026, with the low at -$3.8 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged $169882.4 across 5 years, with a median of $377000.0 in 2025.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 606.02% — and 2026, when it soared 854.11%.
• Damora Therapeutics' Change in Accured Expenses stood at $747000.0 in 2022, then sank by 606.02% to -$3.8 million in 2023, then jumped by 70.93% to -$1.1 million in 2024, then soared by 83.44% to -$182000.0 in 2025, then surged by 2076.37% to $3.6 million in 2026.
• The last three Change in Accured Expenses figures came in at $3.6 million (Q1 2026), -$182000.0 (Q4 2025), and $230000.0 (Q3 2025), per Business Quant data.